Header Logo

Connection

Nirav Shah to Female

Back to Details
This is a "connection" page, showing publications Nirav Shah has written about Female.
Nirav Shah
Connection Strength
0.356
Female
  1. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021 03 11; 137(10):1416-1423.
    View in: PubMed
    Score: 0.028
  2. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575.
    View in: PubMed
    Score: 0.028
  3. Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97.
    View in: PubMed
    Score: 0.026
  4. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. Oncologist. 2019 11; 24(11):1488-1495.
    View in: PubMed
    Score: 0.026
  5. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk. 2019 02; 19(2):95-102.
    View in: PubMed
    Score: 0.024
  6. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 01; 25(1):e33-e38.
    View in: PubMed
    Score: 0.024
  7. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 02; 180(4):534-544.
    View in: PubMed
    Score: 0.023
  8. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386.
    View in: PubMed
    Score: 0.009
  9. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 08 27; 8(16):4320-4329.
    View in: PubMed
    Score: 0.009
  10. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692.
    View in: PubMed
    Score: 0.009
  11. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197.
    View in: PubMed
    Score: 0.009
  12. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood Adv. 2024 05 28; 8(10):2327-2331.
    View in: PubMed
    Score: 0.009
  13. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 05 28; 8(10):2592-2599.
    View in: PubMed
    Score: 0.009
  14. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
    View in: PubMed
    Score: 0.008
  15. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):e775-e781.
    View in: PubMed
    Score: 0.007
  16. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
    View in: PubMed
    Score: 0.007
  17. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 11; 9(22):8468-8479.
    View in: PubMed
    Score: 0.007
  18. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 05 14; 135(20):1739-1749.
    View in: PubMed
    Score: 0.007
  19. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 07 03; 2(7):e196476.
    View in: PubMed
    Score: 0.006
  20. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019 06 11; 3(11):1661-1669.
    View in: PubMed
    Score: 0.006
  21. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
    View in: PubMed
    Score: 0.006
  22. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6.
    View in: PubMed
    Score: 0.006
  23. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist. 2019 07; 24(7):955-962.
    View in: PubMed
    Score: 0.006
  24. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 04; 25(4):827-833.
    View in: PubMed
    Score: 0.006
  25. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 11; 93(11):1394-1401.
    View in: PubMed
    Score: 0.006
  26. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 09; 103(9):1511-1517.
    View in: PubMed
    Score: 0.006
  27. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 09; 53(9):1210-1213.
    View in: PubMed
    Score: 0.006
  28. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 08; 24(8):1664-1670.
    View in: PubMed
    Score: 0.006
  29. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 04; 103(4):717-727.
    View in: PubMed
    Score: 0.006
  30. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant. 2018 01; 24(1):78-85.
    View in: PubMed
    Score: 0.006
  31. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1955-1960.
    View in: PubMed
    Score: 0.006
  32. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 05; 17(5):305-311.e2.
    View in: PubMed
    Score: 0.005
  33. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Transpl Int. 2013 Jun; 26(6):616-22.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.